News

Systemic mastocytosis (SM) can lead to severe osteoporosis, bone pain and fractures, requiring specialized treatment.

Osteoporosis can be the presenting manifestation of systemic mastocytosis (SM), according to a recent case report.

A child was eventually diagnosed with systemic mastocytosis (SM) though he presented with none of the usual systemic symptoms.

Patients with bone marrow mast cell infiltration who do not meet WHO criteria for SM can still have symptoms and are at risk for osteoporosis.

Many cases of cutaneous mastocytosis remain confined to the skin, but some may indicate a risk for systemic mastocytosis (SM).

Avapritinib treatment improves survival outcomes and symptom management in patients with SM, its maker reported.

Physicians continue to raise standards in SM diagnosis and care, allowing patients with advanced SM to achieve better long-term outcomes.

A hematologist detailed several cases of SM that highlighted the need for diligence in diagnosing and managing treatment of ISM.

Patients with SM and venom allergies may face increased risks during immunotherapy if they have a particular genetic variant.

A recent case report illustrated the need for thorough care to prevent adverse postoperative outcomes in patients with SM.